Related Experiment Video
Updated: Jul 17, 2025
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
MicroRNA and gynecological cancers: Focus on miR-195
Amirhossein Davoodvandi1, Mahdi Rafiyan2, Mohammad Ali Mansournia3
1Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Islamic Republic of Iran; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran.
Abstract:
Different cancer types have been shown to have down-regulated expression levels of miR-195 as an anti-tumor agent. MiR-195 family members can inhibit cancer cell proliferation, angiogenesis, epithelial-mesenchymal transition and metastases, immunosuppression, glycolysis, drug resistance, and cancer stem cell development by targeting the 3'-UTR of the mRNA of different pro-tumor genes. MiR-195 identified as a tumor suppressor miR in a variety of cancers, most notably gynecological malignancies such as cervical, endometrial, and ovarian carcinoma. As a result, restoring miR-195 expression should be regarded as a potential therapy for either prevention or treatment of gynecological cancers. This review will present the most recent data about miR-195-mediated anti-tumor effects in gynecological malignancies, emphasizing its downstream signaling pathways and target genes, as well as prospective treatment techniques.
Insights
MicroRNA-195 (miR-195) acts as a tumor suppressor, inhibiting gynecological cancer progression. Restoring miR-195 levels offers a promising therapeutic strategy for these cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNA-195 (miR-195) exhibits down-regulated expression in various cancers, functioning as an anti-tumor agent.
- miR-195 targets pro-tumor genes, inhibiting cancer cell proliferation, angiogenesis, metastasis, and drug resistance.
Purpose of the Study:
- To review the anti-tumor effects of miR-195 in gynecological malignancies.
- To highlight miR-195's role as a tumor suppressor in cervical, endometrial, and ovarian cancers.
- To explore potential therapeutic strategies involving miR-195 restoration.
Main Methods:
- Literature review of recent data on miR-195.
- Analysis of miR-195's downstream signaling pathways and target genes.
- Examination of prospective therapeutic applications in gynecological cancers.
Main Results:
- miR-195 demonstrates significant tumor-suppressive activity in gynecological cancers.
- Targeting pro-tumor genes by miR-195 inhibits key cancer hallmarks.
- Restoration of miR-195 is a potential therapeutic avenue.
Conclusions:
- miR-195 is a critical tumor suppressor in gynecological malignancies.
- Understanding miR-195's mechanisms can lead to novel cancer therapies.
- Restoring miR-195 expression holds promise for gynecological cancer prevention and treatment.
